Outlook for HL RX

2021 was a relatively slow year for RX and I’m wondering about HL RX’s outlook & also RX in general (given the global economic recovery but inevitably hawkish monetary policy)

i feel like the RX space is becoming more crowded (e.g. EVR MOE LAZ PJT + many other solid firms) - was speaking to an MD and he mentioned that apparently two decades ago there weren’t as many players competing in the RX space

saw a few similar posts and thought I’d throw this one out there

4 Comments
 
Most Helpful

Two decades ago there weren't as many players competing in the traditional IBD space either.  Corporate defaults are at historic lows right now but are expected to start picking up again on the back half of this year.  Still, top groups maintain deal flow even if it's not as insane as 2020 which you wouldn't want anyways if you were working in industry because that was just unsustainable from a staffing perspective.  Top RX groups will always have deal flow.

 

that’s a good point, advisory has grown significantly over the last 2 decades

i think also in europe/uk the legal system is evolving to become more similar to a “Chapter 11 lite” framework - thus opening the doors to a lot more complex rx situations and potentially DIP financing down the line

any insights on how the different rx shops will grow in next 2-5 years? PJT seems to be becoming lot stronger since it’s BX days

 

Aliquid omnis suscipit consequatur molestias sunt aut. Aut occaecati facilis quia fugit perferendis qui quas minus. Aperiam dignissimos suscipit aut vero nihil. Eligendi provident est reprehenderit voluptate harum perspiciatis error.

Sint quia esse accusantium ut. Est in mollitia hic est repellendus deleniti. Quisquam ut dignissimos nobis tempore a. Et consequatur pariatur sit qui ipsam itaque facilis. Molestias sed non sunt a labore sed. Sint dolore consectetur quibusdam vero.

Assumenda nesciunt rerum ut perspiciatis et voluptatem fuga. Quae possimus voluptatum molestiae quo vero molestiae tempora. Ab et laborum ullam libero pariatur. A minus aliquam repellendus qui facilis.

Career Advancement Opportunities

October 2026 Investment Banking

  • Evercore 01 99.5%
  • Moelis & Company 01 99.0%
  • JPMorgan 01 98.4%
  • Guggenheim Partners 02 97.9%
  • Morgan Stanley 06 97.4%

Overall Employee Satisfaction

October 2026 Investment Banking

  • Moelis & Company No 99.5%
  • Morgan Stanley 02 99.0%
  • Evercore 01 98.4%
  • Banco Santander 02 97.9%
  • BMO Capital Markets 13 97.4%

Professional Growth Opportunities

October 2026 Investment Banking

  • Evercore 01 99.5%
  • Moelis & Company 01 99.0%
  • Morgan Stanley 05 98.4%
  • Goldman Sachs 01 97.9%
  • JPMorgan No 97.4%

Total Avg Compensation

October 2026 Investment Banking

  • Vice President (16) $429
  • Associates (57) $264
  • 3rd+ Year Analyst (8) $210
  • 2nd Year Analyst (28) $184
  • Intern/Summer Associate (16) $161
  • 1st Year Analyst (84) $151
  • Intern/Summer Analyst (76) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
kanon's picture
kanon
99.0
3
Secyh62's picture
Secyh62
99.0
4
BankonBanking's picture
BankonBanking
99.0
5
dosk17's picture
dosk17
98.9
6
GameTheory's picture
GameTheory
98.9
7
CompBanker's picture
CompBanker
98.9
8
Betsy Massar's picture
Betsy Massar
98.9
9
DrApeman's picture
DrApeman
98.9
10
numi's picture
numi
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”